CC
PDSB icon

Centiva Capital’s PDS Biotechnology PDSB Stock Holding History

Centiva Capital’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-47,966
Closed -$141K – 2483
2024
Q2 		$141K Buy
+47,966
New +$153K ﹤0.01% 1783

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Centiva Capital's PDSB Position: Q3 2024 in Review

Centiva Capital sold out of PDS Biotechnology (PDSB) in Q3 2024, closing a stake of 47,966 shares — an estimated $141K sold.

Centiva Capital first reported a position in PDSB in Q2 2024 and held it in 1 quarter. The position peaked at $141K in Q2 2024. 57 funds tracked by Wall St. Rank hold PDSB as of Q3 2024.

  • Centiva Capital reported no remaining PDS Biotechnology position as of Q3 2024 after selling out during the quarter.
  • Centiva Capital sold 47,966 PDS Biotechnology shares in Q3 2024, an estimated $141K.
  • Centiva Capital first reported a position in PDS Biotechnology in Q2 2024 and held it in 1 quarter.
  • Centiva Capital's PDS Biotechnology position peaked at $141K in Q2 2024.
  • 57 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.